EGFR and non-small cell lung carcinoma: Approximately 10–50% of patients with NSCLC harbor EGFR-activating mutations such as in-frame deletions in exon 19 (Ex19del, particularly E746-A750del) or missense mutation in exon 21 (L858R)2.